Novo Nordisk Clayton
Novo Nordisk, Clayton, North Carolina
Novo Nordisk's Clayton, North Carolina, site was the Danish drugmaker's first US manufacturing site. In 2024 it announced a USD 4.1 billion, 1.4-million-square-foot fill and finish facility there for injectable obesity and chronic disease treatments, to be finished between 2027 and 2029. The employee figure is the nearly 2,500 Novo Nordisk employees in the region, not the Clayton site alone.
- Company
- Novo Nordisk
- Status
- Operating
- Opened
- Not stated
- Employees
- 2,500
- company figure
- Industry
- Pharmaceuticals
- Revised
- November 12, 2026
What is made here
Fill and finish (aseptic manufacturing and finished production) of injectable treatments for obesity and other serious chronic diseases.
Facts
| First US site | Clayton was Novo Nordisk's first manufacturing site in the United States (company: novonordisk.com) |
|---|---|
| 2024 expansion | USD 4.1 billion second fill and finish facility, one of the largest manufacturing investments in Novo Nordisk's history (company: novonordisk.com) |
| Size | The new facility adds 1.4 million square feet of production space, doubling the combined square footage of Novo Nordisk's three existing North Carolina facilities (company: novonordisk.com) |
| Timeline | Construction to be gradually finalized between 2027 and 2029; expected to add 1,000 jobs (company: novonordisk.com) |
| 2016 facility | A facility announced in 2016 across the street was then the largest life sciences investment on North Carolina state record (company: novonordisk.com) |
Figures are as stated by the source named next to each one. Company figures are the company's own claims.
Can you visit?
We haven't found a public tour of this factory. See factory tours in North Carolina.
Sources
- Novo Nordisk: USD 4.1 billion Clayton investment, June 2024 (company, checked November 12, 2026)
Something changed? Send a correction with a link and we'll recheck it.